2019 · European journal of clinical pharmacology · paywalled
Feasibility of and patients' perspective on nilotinib dried blood spot self-sampling
Boons et al.
The finding, in our words
Among 68 chronic myeloid leukaemia patients self-sampling dried blood spots for nilotinib therapeutic drug monitoring at home, 77% of samples were clinically useful. Patients found the procedure easy and not painful, with 75% requiring no assistance, though lower educational level predicted unsuitable samples, underscoring the need for clear instruction.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
The study found that quantitative dried blood spot sampling provided high clinical agreement for tacrolimus and creatinine monitoring, with patients rating the self-collection devices as user-friendly. These results support the feasibility of decentralised therapeutic drug monitoring for immunosuppressants.
Dried blood spot collection proved feasible during parabolic flight, with seventeen of twenty volunteers successfully providing samples for caffeine pharmacokinetic profiling. The method yielded stable metabolic ratios between ground and weightless conditions, and participants reported high satisfaction, suggesting DBS could support therapeutic drug monitoring in remote or extreme environments such as long-term spaceflight.
Home DBS sampling gave testosterone results that agreed well with venous blood in men on intramuscular testosterone undecanoate, but showed falsely high values in those using topical gel, likely from skin contamination. Patients preferred home collection for its convenience, suggesting DBS is viable for decentralised monitoring of injectable testosterone if patients are taught proper technique.